An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

S A Schey; J Cavenagh; R Johnson; J A Child; H Oakervee; R W Jones

doi:10.1016/S0145-2126(03)00027-4

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

S A Schey, J Cavenagh, R Johnson, J A Child, H Oakervee, R W Jones

King's College London

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Abstract

Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase 11 low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings. (C) 2003 Elsevier Science Ltd. All rights reserved.

Original language	English
Pages (from-to)	909 - 914
Number of pages	6
Journal	Leukemia Research
Volume	27
Issue number	10
DOIs	https://doi.org/10.1016/S0145-2126(03)00027-4
Publication status	Published - 1 Oct 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(03)00027-4

Cite this

@article{36d64d1e2b3f437aa03b0c69f0cb0656,

title = "An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment",

abstract = "Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase 11 low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings. (C) 2003 Elsevier Science Ltd. All rights reserved.",

author = "Schey, {S A} and J Cavenagh and R Johnson and Child, {J A} and H Oakervee and Jones, {R W}",

year = "2003",

month = oct,

day = "1",

doi = "10.1016/S0145-2126(03)00027-4",

language = "English",

volume = "27",

pages = "909 -- 914",

journal = "Leukemia Research",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

AU - Schey, S A

AU - Cavenagh, J

AU - Johnson, R

AU - Child, J A

AU - Oakervee, H

AU - Jones, R W

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase 11 low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings. (C) 2003 Elsevier Science Ltd. All rights reserved.

AB - Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase 11 low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings. (C) 2003 Elsevier Science Ltd. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=0037677338&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00027-4

DO - 10.1016/S0145-2126(03)00027-4

M3 - Article

VL - 27

SP - 909

EP - 914

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this